$AMGN Company News NYSE to expand number of co
Post# of 72749
Posted On: 10/17/2014 11:07:52 AM
$AMGN Company News
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
Charting a Fed-induced market whipsaw 11:20 a.m. Oct. 9, 2014 - Michael Ashbaugh
Dow industrials venture to uncharted territory 9:53 a.m. Sept. 17, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Amgen Files Patent Infringement Suit 9:43 a.m. Today - The Wall Street Journal Interactive Edition
Amgen sues Sanofi and Regeneron 9:30 a.m. Today - Seeking Alpha
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement 8:01 a.m. Today - benzinga.com
New Positive Clinical Data Supports Quest Towards Orphan Designations 6:45 a.m. Today - Seeking Alpha
3 Stocks Dragging In The Drugs Industry 1:22 p.m. Oct. 16, 2014 - TheStreet.com
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate 11:46 a.m. Oct. 16, 2014 - Seeking Alpha
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog 1:59 p.m. Oct. 15, 2014 - Zacks.com
'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks 5:00 a.m. Oct. 15, 2014 - TheStreet.com
6 Useful Categories of Stocks 12:02 p.m. Oct. 14, 2014 - GuruFocus.com
Novartis Releases Data on Secukinumab for Plaque Psoriasis - Analyst Blog 5:57 p.m. Oct. 13, 2014 - Zacks.com
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog 5:55 p.m. Oct. 13, 2014 - Zacks.com
UBS Very Positive on Top Biotech Stocks Ahead of Earnings 7:58 a.m. Oct. 13, 2014 - 247WallSt.com
Most Top Industry Groups Fall Harder Than Market 5:35 p.m. Oct. 10, 2014 - Investors Business Daily
Today's Stocks Driving Success For The Drugs Industry 1:03 p.m. Oct. 10, 2014 - TheStreet.com
Amgen spin-out on deck for IPO 11:29 a.m. Oct. 10, 2014 - Seeking Alpha
Short Interest in Biotech Becomes Company Specific 9:24 a.m. Oct. 10, 2014 - 247WallSt.com
Put Amgen Back on Your Buy List 8:52 p.m. Oct. 9, 2014 - InvestorPlace.com
Amgen Up on Positive Phase III Data on Psoriasis Biosimilar - Analyst Blog 3:54 p.m. Oct. 9, 2014 - Zacks.com
UPDATE: Amgen's BiTE Received FDA Priority Review Designation 3:06 p.m. Oct. 9, 2014 - benzinga.com
Portfolio Changes For The Third Quarter 2014 9:14 a.m. Oct. 9, 2014 - Seeking Alpha
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement 9:00 a.m. Today - PR Newswire - PRF
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 6:40 p.m. Oct. 14, 2014 - PR Newswire - PRF
Welfare Initiatives, Clinical Data Presentation, Financing Plan, Regulatory Disclosure, and Positive Drug Trials - Research Reports on Johnson & Johnson, Merck, Medtronic, Covidien and Amgen 8:35 a.m. Oct. 13, 2014 - PR Newswire - PRF
Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia 4:05 p.m. Oct. 9, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 9:15 a.m. Oct. 8, 2014 - PR Newswire - PRF
Global Biosimilar Market Outlook 2018 8:09 p.m. Oct. 1, 2014 - PR Newswire - PRF
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 7:01 p.m. Oct. 1, 2014 - PR Newswire - PRF
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 3:55 p.m. Sept. 29, 2014 - PR Newswire - PRF
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
Q Therapeutics Expands Board of Directors With Appointment of Dr. Hunter Jackson as Independent Member 4:22 p.m. Sept. 23, 2014 - Marketwire
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9:00 p.m. Sept. 14, 2014 - PR Newswire - PRF
Reporting Bias in Clinical Trials: What's the current status? 10:30 a.m. Sept. 10, 2014 - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
Charting a Fed-induced market whipsaw 11:20 a.m. Oct. 9, 2014 - Michael Ashbaugh
Dow industrials venture to uncharted territory 9:53 a.m. Sept. 17, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Amgen Files Patent Infringement Suit 9:43 a.m. Today - The Wall Street Journal Interactive Edition
Amgen sues Sanofi and Regeneron 9:30 a.m. Today - Seeking Alpha
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement 8:01 a.m. Today - benzinga.com
New Positive Clinical Data Supports Quest Towards Orphan Designations 6:45 a.m. Today - Seeking Alpha
3 Stocks Dragging In The Drugs Industry 1:22 p.m. Oct. 16, 2014 - TheStreet.com
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate 11:46 a.m. Oct. 16, 2014 - Seeking Alpha
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog 1:59 p.m. Oct. 15, 2014 - Zacks.com
'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks 5:00 a.m. Oct. 15, 2014 - TheStreet.com
6 Useful Categories of Stocks 12:02 p.m. Oct. 14, 2014 - GuruFocus.com
Novartis Releases Data on Secukinumab for Plaque Psoriasis - Analyst Blog 5:57 p.m. Oct. 13, 2014 - Zacks.com
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog 5:55 p.m. Oct. 13, 2014 - Zacks.com
UBS Very Positive on Top Biotech Stocks Ahead of Earnings 7:58 a.m. Oct. 13, 2014 - 247WallSt.com
Most Top Industry Groups Fall Harder Than Market 5:35 p.m. Oct. 10, 2014 - Investors Business Daily
Today's Stocks Driving Success For The Drugs Industry 1:03 p.m. Oct. 10, 2014 - TheStreet.com
Amgen spin-out on deck for IPO 11:29 a.m. Oct. 10, 2014 - Seeking Alpha
Short Interest in Biotech Becomes Company Specific 9:24 a.m. Oct. 10, 2014 - 247WallSt.com
Put Amgen Back on Your Buy List 8:52 p.m. Oct. 9, 2014 - InvestorPlace.com
Amgen Up on Positive Phase III Data on Psoriasis Biosimilar - Analyst Blog 3:54 p.m. Oct. 9, 2014 - Zacks.com
UPDATE: Amgen's BiTE Received FDA Priority Review Designation 3:06 p.m. Oct. 9, 2014 - benzinga.com
Portfolio Changes For The Third Quarter 2014 9:14 a.m. Oct. 9, 2014 - Seeking Alpha
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement 9:00 a.m. Today - PR Newswire - PRF
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 6:40 p.m. Oct. 14, 2014 - PR Newswire - PRF
Welfare Initiatives, Clinical Data Presentation, Financing Plan, Regulatory Disclosure, and Positive Drug Trials - Research Reports on Johnson & Johnson, Merck, Medtronic, Covidien and Amgen 8:35 a.m. Oct. 13, 2014 - PR Newswire - PRF
Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia 4:05 p.m. Oct. 9, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 9:15 a.m. Oct. 8, 2014 - PR Newswire - PRF
Global Biosimilar Market Outlook 2018 8:09 p.m. Oct. 1, 2014 - PR Newswire - PRF
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 7:01 p.m. Oct. 1, 2014 - PR Newswire - PRF
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 3:55 p.m. Sept. 29, 2014 - PR Newswire - PRF
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
Q Therapeutics Expands Board of Directors With Appointment of Dr. Hunter Jackson as Independent Member 4:22 p.m. Sept. 23, 2014 - Marketwire
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9:00 p.m. Sept. 14, 2014 - PR Newswire - PRF
Reporting Bias in Clinical Trials: What's the current status? 10:30 a.m. Sept. 10, 2014 - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
(0)
(0)